Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
6%
Actinic Keratosis
6%
Acute Leukemia
11%
Acute Myeloid Leukemia
9%
Adenoma
9%
Adverse Event
8%
Allergen
6%
Androgen
7%
Anticarcinogen
10%
Antitumor Activity
9%
Asthma
100%
Atopy
6%
Bile Acid
8%
Biological Marker
12%
Bone Metastasis
13%
Breast Cancer
59%
Cancer Growth
6%
Carcinoma
7%
Chemoradiation Therapy
10%
Chemotherapy
69%
Chronic Obstructive Lung Disease
13%
Cisplatin
35%
Clinical Study
6%
Clinical Trial
32%
Cohort Study
7%
Colon Cancer
15%
Colorectal Adenoma
15%
Colorectal Cancer
8%
Cyclophosphamide
44%
Cytotoxicity
10%
Dacarbazine
10%
Denosumab
13%
Disease
83%
Disease Exacerbation
6%
Disease Free Survival
17%
Docetaxel
10%
Doxorubicin
42%
Drug Resistance
7%
Echo Contrast Medium
7%
Etoposide
21%
Fluorouracil
12%
Fluticasone
8%
Gadolinium Pentetate
8%
Glutathione
10%
Group Trial
7%
Imexon
19%
Immunoglobulin E
7%
Immunotherapy
15%
Infection
8%
Integrin
9%
Interleukin 1
6%
Interleukin 2
7%
Ipilimumab
10%
Letrozole
6%
Liposome
7%
Lung Cancer
11%
Malignant Neoplasm
53%
Matrilysin
10%
Melanoma
42%
Metastasis
12%
Metastatic Breast Cancer
29%
Metastatic Melanoma
17%
Mitomycin
11%
Mouse
42%
Multiple Myeloma
8%
Mycobacterium Bovis BCG
9%
Myeloma
12%
Neoplasm
81%
Neutropenia
6%
Non Small Cell Lung Cancer
29%
Non-Steroidal Anti-Inflammatory Drug
9%
Overall Survival
36%
Paclitaxel
18%
Pancreas Cancer
11%
Pembrolizumab
6%
Perfosfamide
9%
Pharmacokinetics
19%
Phase II Trials
26%
Placebo
43%
Progression Free Survival
21%
Prostate Cancer
45%
Prostate Carcinoma
22%
Prostate Specific Antigen
18%
Protein P53
8%
Randomized Clinical Trial
7%
Recurrent Disease
15%
Remission
20%
Respiratory Tract
9%
Respiratory Tract Disease
6%
Small Cell Carcinoma
6%
Small Cell Lung Cancer
17%
Solid Malignant Neoplasm
15%
Survival Rate
9%
Symptom
25%
Tamoxifen
10%
Tumor Necrosis Factor
10%
Vincristine
8%
Vinorelbine
8%
Wheezing
34%
Zoledronic Acid
9%
Medicine and Dentistry
Acute Leukemia
10%
Acute Myeloid Leukemia
12%
Adenoma
16%
Adjuvant Chemotherapy
8%
Adjuvant Therapy
12%
Airflow
7%
Arm
8%
Asthma
81%
Atopy
7%
Autologous Bone Marrow Transplantation
10%
Biological Marker
16%
Biopsy
11%
Bone Marrow Transplantation
15%
Bone Metastasis
13%
Breast Cancer
56%
Cancer
7%
Cancer Cell
9%
Cell Line
8%
Cell Transplantation
9%
Chemoradiotherapy
6%
Childbirth
23%
Chronic Obstructive Pulmonary Disease
19%
Circulating Tumor Cell
8%
Cisplatin
13%
Clinical Trial
19%
Cohort Analysis
10%
Colonoscopy
10%
Colorectal Adenoma
14%
Cyclophosphamide
16%
Dacarbazine
8%
Denosumab
7%
Disease
71%
Disease Free Survival
12%
Doxorubicin
18%
Drug Megadose
11%
Engraftment
8%
Epithelial Cell
7%
Estrogen Receptor
6%
Etoposide
8%
Extracellular Matrix
7%
Forced Expiratory Volume
11%
Forced Vital Capacity
9%
Gene Expression
11%
Group Trial
8%
Hazard Ratio
15%
Hematopoietic Stem Cell
11%
Imexon
7%
Immunoglobulin E
7%
Immunohistochemistry
7%
Immunotherapy
9%
In Vitro
19%
Infancy
7%
Infection
10%
Integrin
19%
Kalinin
10%
Leukemia Cell
7%
Leukocyte
9%
Lower Respiratory Tract
10%
Lung Cancer
6%
Lung Function
7%
Lymphocyte
10%
Magnetic Resonance Imaging
17%
Malignant Neoplasm
34%
Metabolic Syndrome
6%
Metastatic Breast Cancer
18%
Metastatic Carcinoma
24%
Metastatic Melanoma
13%
Multiple Myeloma
6%
Neoplasm
53%
Nodular Melanoma
30%
Non Small Cell Lung Cancer
19%
Odds Ratio
13%
Oncology
47%
Overall Survival
29%
Pediatrics
16%
Phase II Trials
11%
Placebo
24%
Positron Emission Tomography
8%
Prematurity
7%
Prognostic Factor
9%
Progression Free Survival
12%
Prostate Cancer
44%
Prostate Carcinoma
18%
Prostate Specific Antigen
12%
Prostatic Intraepithelial Neoplasia
8%
Protein P53
11%
Radiation Therapy
21%
Randomized Clinical Trial
6%
Recurrent Disease
15%
Respiratory Disease
18%
Sarcoma
6%
SCID Mouse
9%
Sensitization
9%
Small Cell Lung Cancer
17%
Symptom
25%
Tamoxifen
10%
Transplantation
11%
Tumor Cell
13%
Tumor Microenvironment
7%
Wheeze
46%
Keyphrases
1,25(OH)2D3
5%
Acute Leukemia
9%
Adenoma
5%
Adult Life
6%
AIDS/HIV
7%
Airflow Limitation
5%
Allergy
9%
Allogeneic Bone Marrow Transplantation
5%
Aromatase Inhibitors
6%
Asthma
64%
Asthma children
5%
Asthma Prevalence
5%
Asthma Risk
6%
Atopy
7%
Blastogenic Response
5%
Bone Marrow Transplantation
5%
Bone Metastasis
7%
Breast Cancer
11%
Cancer Patients
5%
CD14
5%
Chemoimmunotherapy
7%
Chemotherapy
18%
Childhood Asthma
12%
Chronic Lymphocytic Leukemia
6%
Cisplatin
10%
Clinical Trials
6%
Colorectal Adenoma
11%
Confidence Interval
17%
Cyclophosphamide
6%
Denosumab
8%
Disease-free Survival
6%
Early Breast Cancer
6%
Early childhood
7%
First Year of Life
5%
Fluticasone Propionate
7%
Forced Expiratory Volume in 1 Second (FEV1)
7%
Gene-environment Interaction
5%
Group Studies
14%
Hazard Ratio
7%
High Risk
5%
Human Prostate
12%
IgE Levels
5%
Imexon
14%
Immunocompetence
5%
Improved Outcomes
5%
In Cancer
6%
Inhaled Corticosteroids
13%
Integrin
9%
Letrozole
6%
Leukemia
5%
Lipopolysaccharide
6%
Lower Respiratory Illness
5%
Lower Respiratory Tract Infection
10%
Lung
5%
Lung Cancer Treatment
5%
Lung Function
14%
Lymphocytes
9%
Matrilysin
7%
Melanoma
8%
Metastatic Breast Cancer
15%
Natural History
5%
Non-small Cell Lung Cancer (NSCLC)
5%
Odds Ratio
8%
Overall Survival
12%
Overexpression
5%
Pediatric Asthma
6%
Persistent Asthma
5%
Persistent Wheezing
5%
Phase II Study
10%
Phase II Trial
12%
Placebo
9%
Polymorphism
6%
Preschool children
8%
Progression-free Survival
6%
Prostaglandin E2
5%
Prostate
6%
Prostate Cancer
16%
Prostate Carcinoma
7%
Randomized Controlled Trial
5%
Randomized Placebo-controlled Trial
5%
Randomized Trial
9%
Remission
8%
Response Rate
6%
Risk Factors
5%
Selenium
7%
Small Cell Lung Cancer
6%
Soluble CD14 (sCD14)
6%
Southwest Oncology Group
27%
Total Prostate-specific Antigen
5%
Tucson
8%
Tumor
15%
Tumor Cells
5%
Tumor Necrosis Factor-α
6%
Vitamin D Metabolites
5%
Wheezing
26%
Zoledronic Acid
6%